Breaking News, Collaborations & Alliances, Trials & Filings

Biokin Selects Cryoport’s Solutions for Pending Trials

Cryoport's full suite of temperature-controlled solutions will support Biokin Pharma's pending Phase I and II clinical trials in immuno-oncology in U.S. & China

Biokin Pharma and Cryoport announced Cryoport’s full suite of temperature-controlled solutions will support Biokin Pharma’s pending Phase I and II clinical trials in immuno-oncology in both the U.S. and China.  Biokin Pharma, is a biopharmaceutical company based in China focused on the treatment of cancer through developing novel therapeutic antibodies and antibody-drug conjugates. Its wholly-owned subsidiary SystImmune, which is funded in part by OrbiMed, was formed to advance it...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters